Telix Pharmaceuticals Ltd — Capital/Financing Update 2020

Dec 13, 2020

Telix Pharmaceuticals Limited ACN 616 620 369 Suite 401, 55 Flemington Road North Melbourne Victoria, 3051 Australia

==> picture [146 x 81] intentionally omitted <==

Telix Pharmaceuticals Completes Acquisition of TheraPharm GmbH

Melbourne (Australia) and Baar (Switzerland) – 14[th] December 2020 . Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today announces it has completed the acquisition of TheraPharm GmbH (‘TheraPharm’) from Scintec Diagnostics GmbH (‘Scintec’).

Having satisfied the necessary conditions for completion, which included the novation of certain intellectual property and personnel agreements, Telix has acquired all of the issued capital of TheraPharm for the final upfront consideration of EUR €10.2M (~AUD $16.5M), comprising 4,312,151 fully paid ordinary Telix shares, issued at a price of AUD $3.75 per share, based on the 10-day volume-weighted average price (‘VWAP’) of Telix shares up to and including 10[th] December 2020, and a EUR €0.2M (~AUD $0.3M) completion payment. Under the terms of the Share Sale Agreement, Scintec will have its shareholding subject to escrow for 24 months, ending 14[th] December 2022.[1]

About Telix Pharmaceuticals Limited

Telix is a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne, Australia with international operations in Belgium, Japan and the United States. Telix is developing a portfolio of clinical-stage oncology products that address significant unmet medical needs in prostate, kidney and brain cancer. Telix is listed on the Australian Securities Exchange (ASX: TLX). For more information visit www.telixpharma.com.

About TheraPharm GmbH

TheraPharm is a biotechnology company specialised in the research, development and manufacturing of monoclonal antibodies for targeted radiation of hematopoietic malignant and nonmalignant diseases, lymphoproliferative diseases, conditioning for allogeneic stem cells as well as in diagnostics of inflammatory diseases and bone marrow metastases.

Telix Corporate Contact

Telix Investor Relations

Dr. Christian Behrenbruch Dr. David N. Cade Telix Pharmaceuticals Limited Telix Pharmaceuticals Limited CEO CBO and Head of Investor Relations Email: Christian@telixpharma.com Email: david.cade@telixpharma.com

Important Information

This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States, or in any other jurisdiction in which such an offer would be illegal. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933 (the “U.S. Securities Act”), or under the securities laws of any state or other jurisdiction of the United States and may not be offered or sold within the United States, unless the securities have been registered under the U.S. Securities Act or an exemption from the registration requirements of the U.S. Securities Act is available. None of the technologies or products described in this document have received a marketing authorisation in any jurisdiction. This announcement has been authorised for release by Dr Christian Behrenbruch, Managing Director and Chief Executive Officer.

1 See ASX disclosure 30th November 2020.

Page 1